The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression

Nat Commun. 2022 Feb 9;13(1):759. doi: 10.1038/s41467-022-28407-4.

Abstract

Despite the remarkable success of immunotherapy in many types of cancer, pancreatic ductal adenocarcinoma has yet to benefit. Innate immune cells are critical to anti-tumor immunosurveillance and recent studies have revealed that these populations possess a form of memory, termed trained innate immunity, which occurs through transcriptomic, epigenetic, and metabolic reprograming. Here we demonstrate that yeast-derived particulate β-glucan, an inducer of trained immunity, traffics to the pancreas, which causes a CCR2-dependent influx of monocytes/macrophages to the pancreas that display features of trained immunity. These cells can be activated upon exposure to tumor cells and tumor-derived factors, and show enhanced cytotoxicity against pancreatic tumor cells. In orthotopic models of pancreatic ductal adenocarcinoma, β-glucan treated mice show significantly reduced tumor burden and prolonged survival, which is further enhanced when combined with immunotherapy. These findings characterize the dynamic mechanisms and localization of peripheral trained immunity and identify an application of trained immunity to cancer.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Bacteria
  • Female
  • Fungi
  • Immunity*
  • Immunity, Innate / immunology
  • Lectins, C-Type
  • Male
  • Mice
  • Myeloid Cells
  • Pancreas / drug effects*
  • Pancreatic Neoplasms / drug therapy*
  • Receptors, CCR2 / genetics
  • beta-Glucans / immunology

Substances

  • Antineoplastic Agents
  • Ccr2 protein, mouse
  • Lectins, C-Type
  • Receptors, CCR2
  • beta-Glucans
  • dectin 1